This study is testing a drug called Epcoritamab as a "consolidation therapy" for people with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). Consolidation therapy is given after initial treatment to help prevent the cancer from coming back. You might be able to join if you've already received at least 12 months of a specific type of treatment (acalabrutinib or zanubrutinib, possibly with obinutuzumab) for your CLL or SLL. The main goal is to see if Epcoritamab can help patients achieve a very low level of leukemia cells (called "undetectable Minimal Residual Disease Complete Remission" or uMRD CR) that allows them to stop treatment and have a lasting remission. The study is currently unclear on its recruitment status.

Study design

This is a Phase 2, multicenter study involving 22 participants. It uses a specific design to determine the best dose of Epcoritamab.

What's involved

If you join, you would receive Epcoritamab injections for up to 12 cycles while continuing your current BTKi therapy. Your disease response will be checked after 6 and 12 cycles using blood tests, CT scans, and possibly bone marrow biopsies.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint for success is measured approximately 336 days after the start of the first cycle of Epcoritamab.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.